Table I.
Regulation of signaling pathways mediated by UCA1 as a competitive endogenous RNA of miRNAs.
| miRNA | Target gene | Signaling pathways | Biological functions | Diseases | (Refs.) |
|---|---|---|---|---|---|
| miR-193a | CDK6 | PI3K/AKT, ERK/MAPK and Notch | Migration, invasion and apoptosis | Glioma | (61) |
| miR-126 | RAC1 | PI3K/AKT and JAK/STAT | Proliferation, migration and invasion | AML | (62) |
| miR-582 | CREB1 | PI3K/AKT/mTOR | EMT | Osteosarcoma | (72) |
| miR-143 | HK2 | PI3K/AKT/mTOR | Glycolysis | Bladder cancer | (79) |
| miR-200c | – | PI3K/AKT/mTOR, AMPK and Wnt/β-catenin | Proliferation, migration and invasion | Hemangioma | (78) |
| miR-185-5p | MMP-9 | Wnt/β-catenin | EMT | Melanoma | (84) |
| miR-122 | – | PI3K/AKT/mTOR and JNK/p38 MAPK | Apoptosis | AMI | (76) |
| miR-122 | CLIC1 | ERK/MAPK | Metastasis | CCA | (89) |
| miR-203 | MEF2C | NF-κB | Inflammation | Epilepsy | (93) |
| miR-331-3p | IL6R | JAK2/STAT3 | Proliferation and apoptosis | MM | (98) |
| miR-15a | – | Hippo and JNK/p38 MAPK | Proliferation and EMT | Thyroid cancer | (90) |
| miR-124 | JAG1 | Notch | Invasion and EMT | Tongue cancer | (46) |
| miR-145-5p | SMAD5 | TGF-β/SMAD | Chondrogenic differentiation | Osteoarthritis | (103) |
| miR-124-3p | SMAD4 | TGF-β/SMAD | Chondrogenic differentiation | Osteoarthritis | (103) |
| miR-1 | Slug | TGF-β/SMAD | EMT | BC and glioma | (33,104) |
| miR-203a | |||||
| miR-182-5p | DLL4 | Notch | Proliferation, migration and apoptosis | Renal cancer | (11) |
| miR-143 | MDM2 | PI3K/AKT/mTOR and p53 | Apoptosis | AMI | (77) |
UCA1, urothelial carcinoma associated 1; miR, microRNA; CDK6, cyclin-dependent kinase 6; AMI, acute myocardial infarction; AML, acute myeloid leukemia; BC, breast cancer; CCA, cholangiocarcinoma; CLIC1, chloride intracellular channel 1; CREB1, cAMP response element-binding protein 1; DLL4, Delta-like 4; EMT, epithelial-to-mesenchymal transition; ERK, extracellular signal-regulated kinase; HK2, hexokinase 2; JAG1, jagged 1; MAPK, mitogen-activated protein kinases; MM, multiple myeloma; MMP-9, matrix metalloproteinase-9; mTOR, mammalian target of rapamycin; PE, pre-eclampsia; RAC1, RAS-related C3 botulinus toxin substrate 1; TGF-β, transforming growth factor-β; -, not available.